New cancer drug combo tested in japanese patients
NCT ID NCT07176975
Summary
This early-stage study aims to find a safe dose of a new drug, BI 1831169, when given with an existing immunotherapy (an anti-PD1 antibody) to Japanese adults with advanced solid tumors that have spread. The goal is to see how much of the new drug people can tolerate and to check for side effects. Participants will receive the drug combination for up to one year, with regular health and tumor monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.